Further processing options
A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.
Saved in:
Journal Title: | Journal of Clinical Oncology |
---|---|
Authors and Corporations: | , , , , , , , , , , , , , , , , |
In: | Journal of Clinical Oncology, 36, 2018, 15_suppl, p. e15545-e15545 |
Type of Resource: | E-Article |
Language: | English |
published: |
American Society of Clinical Oncology (ASCO)
|
Subjects: |